A-Alpha Bio Raises $22.4 Million in Series A2

by Kay Aloha Villamor in July 26th, 2023

A-Alpha Bio, a Seattle, WA-based synthetic biology and machine learning (ML) company specializing in measuring and engineering protein-protein interactions, secured $22.4 million in Series A2 funding round. 

The round was led by previous investor Perceptive Xontogeny Ventures, with significant support from Madrona and other existing investors. Series A2 funding round brings A-Alpha Bio's total funding to $51 million.

Additionally, Breakout Ventures joined the round as a new investor, and Lindy Fishburne, Managing Partner at Breakout Ventures, will join the board as an observer.

The newly secured funding will be utilized to further develop A-Alpha Bio's AlphaSeq and AlphaBind platforms and accelerate the advancement of their oncology-focused internal pipeline. The company's primary mission is to expedite therapeutic discovery to improve human health.

"A-Alpha’s rapid progress has been inspiring, with the team's talent and commitment paving the way for extensive applications of our platforms and fostering remarkable collaborations," said David Younger, Co-Founder and CEO. "The continued support from our investors empowers us to focus on our mission of improving human health by progressing our internal programs and further developing our unique platforms. We are particularly excited to welcome our new Board Observer, Lindy Fishburne, who brings a wealth of industry expertise and shares our vision for the future of medicine empowered by synthetic biology and machine learning."

Company: A-Alpha Bio, Inc.

Raised: $22.4M

Round: Series A2

Funding Month: July 2023

Lead Investors: Perceptive Xontogeny Ventures

Additional Investors: Madrona and Breakout Ventures

Company Website: https://www.aalphabio.com/

Software Category: Protein-Protein Interaction Data Platform

About the Company: Founded in 2017, A-Alpha Bio is a protein-protein interaction company that uses synthetic biology and machine learning to measure, discover, predict, and engineer protein-protein interactions. Its mission is to improve human health by unlocking the potential of protein-protein interactions.

Source: https://www.prweb.com/releases/a_alpha_bio_raises_22_4m_in_series_a2_to_scale_protein_protein_interaction_data_platforms_and_accelerate_internal_pipeline_development/prweb19455230.htm



Your cart